Clinical trials: Food Labeling
Healthy Volunteers
A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants
This is a two-part, open-label, healthy volunteer study. Part I will investigate the relative bioavailability of capsule and tablet formulations of RO7017773.
- Trial name
- NCT03847987
- Testing
- RO7017773 Phase I Capsule, RO7017773 Phase II Tablet Unflavored, RO7017773 Phase II Tablet Sweetened/Flavored
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food
The main objective is to investigate the effect of food on the pharmacokinetics of BI 1015550 Formulation C2.
- Trial name
- NCT06415045
- Testing
- BI 1015550
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood
SRD-Part: To investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses (SRD) of BI 1569912 BA/FE-Part: To investigate (a) the relative bioavailability (BA) of BI 1569912 and (b) the…
- Trial name
- NCT04445090
- Testing
- BI 1569912
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors, Lymphoma
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
The purpose of this study is to evaluate the effect of food on the single-dose pharmacokinetics (PK) of alisertib administered as an enteric-coated tablet (ECT) formulation in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT01898078
- Testing
- Alisertib
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy Participants
A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.
The primary goal of this phase 1 study is to evaluate the effect of food and cobicistat on the pharmacokinetics of plixorafenib in healthy participants.
- Trial name
- NCT06385119
- Testing
- Plixorafenib, Cobicistat
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fore Biotherapeutics
Healthy
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use
To investigate the steady state pharmacokinetics of different formulation of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ).
- Trial name
- NCT02129192
- Testing
- Amlodipine 5mg capsule, T80/H12.5 mg FDC tablet, T80/A5/H12.5 mg FDC tablet
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants
The main purpose of this study is to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) after meals and on an empty stomach.
- Trial name
- NCT06180980
- Testing
- Pirtobrutinib
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants
The purpose of this study is to assess the relative bioavailability of a TAK-648 tablet compared with a TAK-648 oral solution, and to assess the effect of food on the bioavailability of a TAK-648 tablet in healthy participants.
- Trial name
- NCT02480439
- Testing
- TAK-648 Tablet, TAK-648 Oral Solution
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
Food Preferences
A Trial of Behavioral Economic Interventions Among Food Pantry Clients
Obesity, unhealthy dietary habits, and food insecurity are major public health concerns, especially affecting individuals living in poverty.
- Trial name
- NCT04011384
- Testing
- Behavioral economic intervention of online purchasing at a food pantry
- Where
- United States
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Schizophrenia
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
- Trial name
- NCT06572449
- Testing
- KarXT
- Where
- 6 sites in United States
- Volunteers
- 173 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Smoking Cessation
A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation
This will be an open-label, randomised, 2-treatment period, single-dose crossover study to determine the comparative bioavailability and renal elimination following single-dose administration of 3.0 mg cytisine in healthy smokers…
- Trial name
- NCT03509948
- Testing
- cytisine
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Achieve Life Sciences
Peanut Allergy
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
- Trial name
- NCT03292484
- Testing
- AR101
- Where
- 93 sites in United States, Canada and 8 more
- Volunteers
- 911 people
- Sponsor
- Aimmune Therapeutics, Inc.
Healthy
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
The primary objective of the current study is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet (formulation A1, Treatment A, Test) compared to BI 10773 given in free combination…
- Trial name
- NCT01189201
- Testing
- BI 10773/linagliptin, BI 10773/linagliptin SID, BI 10773/linagliptin FDC
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
This 2-part study will be carried out on healthy elderly subjects to evaluate relative bioavailability of danirixin formulations.
- Trial name
- NCT03457727
- Testing
- Danirixin, Omeprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Participants
A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults
The purpose of the study is to evaluate the effect of a low-fat and high-fat meal on the medicine called PF-07284890 following three single doses PF-07284890.
- Trial name
- NCT05349864
- Testing
- PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)
A study to compare the pharmacokinetics (PK) of the dry filled capsule (DFC) \& oral compressed tablet (OCT) formulations of MK-0941-009 \& to assess the effect of food on the OCT formulation.
- Trial name
- NCT00567112
- Testing
- 10 mg MK-0941 DFC (fasted), 10 mg MK-0941 OCT (after meal), 10 mg MK-0941 OCT (before meal)
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Nutrition, Food Selection
Front-of-Package Nutrition Labels
The goal of this study is to determine whether certain front-of-package food labeling systems improve the healthfulness of consumers' grocery selections.
- Conditions
- Nutrition, Food Selection, Food Preferences, Dietary Habits
- Trial name
- NCT06516627
- Testing
- Positive Labels, Spectrum Labels, FDA High In Labels
- Where
- United States
- Volunteers
- 6,002 people, healthy volunteers welcome
- Sponsor
- Harvard Pilgrim Health Care
Healthy Volunteers
A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation
The purpose of this study is to determine the pharmacokinetic (PK) of a single oral dose of TAK-831 400 milligram (mg) in the fasted state and to estimate the effect of food on the PK of a single oral dose of TAK-831 400 mg when…
- Trial name
- NCT03101293
- Testing
- TAK-831
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Advanced Solid Tumors, Solid Tumors
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft…
- Conditions
- Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer
- Trial name
- NCT04672460
- Testing
- TALZENNA capsule, Talazoparib soft gel capsule
- Where
- 31 sites in United States, Australia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Healthy
A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.
The purpose of this study is to understand the effect of tablet formulation and presence of food on the study medicine PF-06821497 in healthy adult participants.
- Trial name
- NCT05767905
- Testing
- PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer